Edit |   |
---|---|
Antigenic Specificity | CD25, Human |
Clone | REA945 |
Host Species | Recombinant Human |
Reactive Species | human, nonhuman primate |
Isotype | IgG1 |
Format | phycoerythrin (PE) conjugate |
Size | 100 tests in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD25 Antibody, anti-human, PE, REAfinity™. Clone REA945 recognizes the human CD25 antigen, a 28 kDa glycoprotein also known as the low-affinity interleukin-2 receptor alpha chain (IL-2Rα). CD25 is expressed on activated T and B cells, on macrophages, and on a subset of non-activated CD4+ regulatory T cells. CD25 plays an essential role in the regulation of immune tolerance by controlling regulatory T cells activity. The CD25 antigen contains three epitope regions called A, B, and C. Clone REA945 recognizes epitope region B. | Additional information: Clone REA945 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | IL2RA, IDDM10, IL2R, TCGFR, p55, Tac, IL-2Rα |
Gene, Accession # | Gene ID: 3559 |
Catalog # | 130-115-534 |
Price | $310 |
Order / More Info | CD25, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Sakaguchi, S. et al. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164. | Shevach, E. M. (2001) Certified professionals: CD4+CD25+ suppressor T cells. J. Exp. Med. 193 (11): F41-F46. | Maloy, K. J. et al. (2001) Regulatory T cells in the control of immune pathology. Nat Immunol 2 (9): 816-822. | Lamprecht, B. et al. (2008) Aberrant expression of the T?2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112 (8): 3339-3347. | Chaput, N. et al. (2013) Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome. Oncoimmunology 2 (2): e23080. |